Arrowhead Pharma (ARWR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 09/30
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -109,328 | 28,242 | 30,114 | 13,993 | 192,645 |
| Depreciation Amortization | 10,900 | 6,390 | 18,139 | 12,997 | 8,531 |
| Accounts receivable | -8,861 | -212,046 | -56,967 | -9,841 | -2,365 |
| Accounts payable and accrued liabilities | 13,073 | 15,263 | 6,286 | 21,662 | -1,717 |
| Other Working Capital | 126,361 | -61,793 | -18,235 | 20,125 | 38,085 |
| Other Operating Activity | 65,778 | 237,425 | 200,215 | 100,125 | 78,602 |
| Operating Cash Flow | $97,923 | $13,481 | $179,552 | $159,061 | $313,781 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 148,266 | 115,339 | -796,258 | -774,616 | 347,402 |
| PPE Investments | -4,713 | -2,148 | -22,666 | -15,177 | -12,813 |
| Purchase Of Investment | -1,061,577 | -136,933 | N/A | N/A | -677,892 |
| Sale Of Investment | N/A | N/A | 689,630 | 587,880 | N/A |
| Investing Cash Flow | $-918,024 | $-23,742 | $-129,294 | $-201,913 | $-343,303 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | 10,260 | N/A | N/A |
| Debt Issued | 700,000 | N/A | N/A | 7,098 | N/A |
| Debt Repayment | -84,506 | -66,680 | -201,625 | -201,625 | -151,625 |
| Common Stock Issued | 286,976 | 51,930 | 270,371 | 269,864 | 269,641 |
| Dividend Paid | -41,514 | N/A | N/A | N/A | N/A |
| Other Financing Activity | -79,989 | 0 | -5,000 | -5,000 | -5,000 |
| Financing Cash Flow | $780,967 | $-14,750 | $74,006 | $70,337 | $113,016 |
| Exchange Rate Effect | 1,103 | 106 | -401 | -377 | -470 |
| Beginning Cash Position | 226,548 | 226,548 | 102,685 | 102,685 | 102,685 |
| End Cash Position | 188,517 | 201,643 | 226,548 | 129,793 | 185,709 |
| Net Cash Flow | $-38,031 | $-24,905 | $123,863 | $27,108 | $83,024 |
| Free Cash Flow | |||||
| Operating Cash Flow | 97,923 | 13,481 | 179,552 | 159,061 | 313,781 |
| Capital Expenditure | -4,713 | -2,148 | -22,666 | -15,177 | -12,813 |
| Free Cash Flow | 93,210 | 11,333 | 156,886 | 143,884 | 300,968 |